JP2002519325A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002519325A5 JP2002519325A5 JP2000556786A JP2000556786A JP2002519325A5 JP 2002519325 A5 JP2002519325 A5 JP 2002519325A5 JP 2000556786 A JP2000556786 A JP 2000556786A JP 2000556786 A JP2000556786 A JP 2000556786A JP 2002519325 A5 JP2002519325 A5 JP 2002519325A5
- Authority
- JP
- Japan
- Prior art keywords
- pyrrolo
- group
- ethyl
- oxy
- acetic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 150000001875 compounds Chemical class 0.000 description 17
- 229910052739 hydrogen Inorganic materials 0.000 description 14
- 239000001257 hydrogen Substances 0.000 description 14
- 125000000217 alkyl group Chemical group 0.000 description 12
- -1 pyrrolo [2,3-d] pyrimidine compound Chemical class 0.000 description 11
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 7
- 150000002431 hydrogen Chemical class 0.000 description 7
- 125000001188 haloalkyl group Chemical group 0.000 description 6
- 239000002253 acid Substances 0.000 description 5
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 5
- 125000005843 halogen group Chemical group 0.000 description 5
- 230000002452 interceptive effect Effects 0.000 description 5
- 229910052760 oxygen Inorganic materials 0.000 description 5
- 239000001301 oxygen Substances 0.000 description 5
- 125000001424 substituent group Chemical group 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- 125000005647 linker group Chemical group 0.000 description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- 239000011593 sulfur Chemical group 0.000 description 4
- 229910052717 sulfur Chemical group 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 125000002837 carbocyclic group Chemical group 0.000 description 3
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 125000000623 heterocyclic group Chemical group 0.000 description 3
- 239000000651 prodrug Chemical class 0.000 description 3
- 229940002612 prodrug Drugs 0.000 description 3
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 125000000027 (C1-C10) alkoxy group Chemical group 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 125000003545 alkoxy group Chemical group 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000012453 solvate Chemical class 0.000 description 2
- 125000001544 thienyl group Chemical group 0.000 description 2
- 125000004455 (C1-C3) alkylthio group Chemical group 0.000 description 1
- 125000006699 (C1-C3) hydroxyalkyl group Chemical group 0.000 description 1
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 description 1
- 125000006645 (C3-C4) cycloalkyl group Chemical group 0.000 description 1
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 1
- WPEVNKWGKHIBOA-UHFFFAOYSA-N 2-(7-benzyl-6-ethyl-2-methoxy-5-oxamoylpyrrolo[2,3-d]pyrimidin-4-yl)oxyacetic acid Chemical compound CCC1=C(C(=O)C(N)=O)C2=C(OCC(O)=O)N=C(OC)N=C2N1CC1=CC=CC=C1 WPEVNKWGKHIBOA-UHFFFAOYSA-N 0.000 description 1
- WENVYWUWPIAIIR-UHFFFAOYSA-N 2-(7-benzyl-6-ethyl-5-oxamoyl-2-phenylsulfanylpyrrolo[2,3-d]pyrimidin-4-yl)oxyacetic acid Chemical compound N1=C2N(CC=3C=CC=CC=3)C(CC)=C(C(=O)C(N)=O)C2=C(OCC(O)=O)N=C1SC1=CC=CC=C1 WENVYWUWPIAIIR-UHFFFAOYSA-N 0.000 description 1
- MJXZAPRPPVABHR-UHFFFAOYSA-N 2-[6-ethyl-2-methylsulfanyl-5-oxamoyl-7-[(2-phenylphenyl)methyl]pyrrolo[2,3-d]pyrimidin-4-yl]oxyacetic acid Chemical compound CCC1=C(C(=O)C(N)=O)C2=C(OCC(O)=O)N=C(SC)N=C2N1CC1=CC=CC=C1C1=CC=CC=C1 MJXZAPRPPVABHR-UHFFFAOYSA-N 0.000 description 1
- CDQYBTDSVYJQCA-UHFFFAOYSA-N 2-[6-ethyl-2-methylsulfanyl-5-oxamoyl-7-[[3-(trifluoromethyl)phenyl]methyl]pyrrolo[2,3-d]pyrimidin-4-yl]oxyacetic acid Chemical compound CCC1=C(C(=O)C(N)=O)C2=C(OCC(O)=O)N=C(SC)N=C2N1CC1=CC=CC(C(F)(F)F)=C1 CDQYBTDSVYJQCA-UHFFFAOYSA-N 0.000 description 1
- RSSFXDQLFYNXKQ-UHFFFAOYSA-N 2-[6-ethyl-5-oxamoyl-7-[(2-phenylphenyl)methyl]pyrrolo[2,3-d]pyrimidin-4-yl]oxyacetic acid Chemical compound CCC1=C(C(=O)C(N)=O)C2=C(OCC(O)=O)N=CN=C2N1CC1=CC=CC=C1C1=CC=CC=C1 RSSFXDQLFYNXKQ-UHFFFAOYSA-N 0.000 description 1
- VQESUOQWWMOUFN-UHFFFAOYSA-N 2-[6-ethyl-5-oxamoyl-7-[[3-(trifluoromethyl)phenyl]methyl]pyrrolo[2,3-d]pyrimidin-4-yl]oxyacetic acid Chemical compound CCC1=C(C(=O)C(N)=O)C2=C(OCC(O)=O)N=CN=C2N1CC1=CC=CC(C(F)(F)F)=C1 VQESUOQWWMOUFN-UHFFFAOYSA-N 0.000 description 1
- SRAPMULSNIDCQT-UHFFFAOYSA-N 2-[6-ethyl-7-[(3-fluorophenyl)methyl]-2-methylsulfanyl-5-oxamoylpyrrolo[2,3-d]pyrimidin-4-yl]oxyacetic acid Chemical compound CCC1=C(C(=O)C(N)=O)C2=C(OCC(O)=O)N=C(SC)N=C2N1CC1=CC=CC(F)=C1 SRAPMULSNIDCQT-UHFFFAOYSA-N 0.000 description 1
- YURRGXLFZZKHEH-UHFFFAOYSA-N 2-[6-ethyl-7-[(3-fluorophenyl)methyl]-5-oxamoylpyrrolo[2,3-d]pyrimidin-4-yl]oxyacetic acid Chemical compound CCC1=C(C(=O)C(N)=O)C2=C(OCC(O)=O)N=CN=C2N1CC1=CC=CC(F)=C1 YURRGXLFZZKHEH-UHFFFAOYSA-N 0.000 description 1
- SWMZZGWHRAEFBN-UHFFFAOYSA-N 2-[7-[(3-chlorophenyl)methyl]-6-ethyl-2-methylsulfanyl-5-oxamoylpyrrolo[2,3-d]pyrimidin-4-yl]oxyacetic acid Chemical compound CCC1=C(C(=O)C(N)=O)C2=C(OCC(O)=O)N=C(SC)N=C2N1CC1=CC=CC(Cl)=C1 SWMZZGWHRAEFBN-UHFFFAOYSA-N 0.000 description 1
- KAXAMNGVKFDQEN-UHFFFAOYSA-N 2-[7-[(3-chlorophenyl)methyl]-6-ethyl-5-oxamoylpyrrolo[2,3-d]pyrimidin-4-yl]oxyacetic acid Chemical compound CCC1=C(C(=O)C(N)=O)C2=C(OCC(O)=O)N=CN=C2N1CC1=CC=CC(Cl)=C1 KAXAMNGVKFDQEN-UHFFFAOYSA-N 0.000 description 1
- JJTNLWSCFYERCK-UHFFFAOYSA-N 7h-pyrrolo[2,3-d]pyrimidine Chemical compound N1=CN=C2NC=CC2=C1 JJTNLWSCFYERCK-UHFFFAOYSA-N 0.000 description 1
- UISCPYYXHAJPON-UHFFFAOYSA-N CCc([n]1Cc2ccccc2)c(C(C(N)=O)=O)c2c1ncnc2OCC(OC)=O Chemical compound CCc([n]1Cc2ccccc2)c(C(C(N)=O)=O)c2c1ncnc2OCC(OC)=O UISCPYYXHAJPON-UHFFFAOYSA-N 0.000 description 1
- ZUSWDTWYONAOPH-UHFFFAOYSA-N [2-(trifluoromethyl)phenyl]hydrazine;hydrochloride Chemical group [Cl-].[NH3+]NC1=CC=CC=C1C(F)(F)F ZUSWDTWYONAOPH-UHFFFAOYSA-N 0.000 description 1
- 125000004062 acenaphthenyl group Chemical group C1(CC2=CC=CC3=CC=CC1=C23)* 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 125000000392 cycloalkenyl group Chemical group 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- 125000006125 ethylsulfonyl group Chemical group 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- SQVKJRUWCAGTQT-UHFFFAOYSA-N methyl 2-(7-benzyl-6-ethyl-2-methoxy-5-oxamoylpyrrolo[2,3-d]pyrimidin-4-yl)oxyacetate Chemical compound CCC1=C(C(=O)C(N)=O)C2=C(OCC(=O)OC)N=C(OC)N=C2N1CC1=CC=CC=C1 SQVKJRUWCAGTQT-UHFFFAOYSA-N 0.000 description 1
- UTXVGTYLJHXCFV-UHFFFAOYSA-N methyl 2-(7-benzyl-6-ethyl-2-methylsulfanyl-5-oxamoylpyrrolo[2,3-d]pyrimidin-4-yl)oxyacetate Chemical compound CCC1=C(C(=O)C(N)=O)C2=C(OCC(=O)OC)N=C(SC)N=C2N1CC1=CC=CC=C1 UTXVGTYLJHXCFV-UHFFFAOYSA-N 0.000 description 1
- UIWQNCFJKCMNQC-UHFFFAOYSA-N methyl 2-(7-benzyl-6-ethyl-5-oxamoyl-2-phenylsulfanylpyrrolo[2,3-d]pyrimidin-4-yl)oxyacetate Chemical compound N1=C2N(CC=3C=CC=CC=3)C(CC)=C(C(=O)C(N)=O)C2=C(OCC(=O)OC)N=C1SC1=CC=CC=C1 UIWQNCFJKCMNQC-UHFFFAOYSA-N 0.000 description 1
- HOOQFNAKLQAFPR-UHFFFAOYSA-N methyl 2-[6-ethyl-2-methylsulfanyl-5-oxamoyl-7-[(2-phenylphenyl)methyl]pyrrolo[2,3-d]pyrimidin-4-yl]oxyacetate Chemical compound CCC1=C(C(=O)C(N)=O)C2=C(OCC(=O)OC)N=C(SC)N=C2N1CC1=CC=CC=C1C1=CC=CC=C1 HOOQFNAKLQAFPR-UHFFFAOYSA-N 0.000 description 1
- FPDGJKOVFVDIQT-UHFFFAOYSA-N methyl 2-[6-ethyl-2-methylsulfanyl-5-oxamoyl-7-[[2-(trifluoromethyl)phenyl]methyl]pyrrolo[2,3-d]pyrimidin-4-yl]oxyacetate Chemical compound CCC1=C(C(=O)C(N)=O)C2=C(OCC(=O)OC)N=C(SC)N=C2N1CC1=CC=CC=C1C(F)(F)F FPDGJKOVFVDIQT-UHFFFAOYSA-N 0.000 description 1
- FYCIHLAQTWFKNK-UHFFFAOYSA-N methyl 2-[6-ethyl-2-methylsulfanyl-5-oxamoyl-7-[[3-(trifluoromethyl)phenyl]methyl]pyrrolo[2,3-d]pyrimidin-4-yl]oxyacetate Chemical compound CCC1=C(C(=O)C(N)=O)C2=C(OCC(=O)OC)N=C(SC)N=C2N1CC1=CC=CC(C(F)(F)F)=C1 FYCIHLAQTWFKNK-UHFFFAOYSA-N 0.000 description 1
- CIBVUOKJGYZYGA-UHFFFAOYSA-N methyl 2-[6-ethyl-5-oxamoyl-7-[(2-phenylphenyl)methyl]pyrrolo[2,3-d]pyrimidin-4-yl]oxyacetate Chemical compound CCC1=C(C(=O)C(N)=O)C2=C(OCC(=O)OC)N=CN=C2N1CC1=CC=CC=C1C1=CC=CC=C1 CIBVUOKJGYZYGA-UHFFFAOYSA-N 0.000 description 1
- QJXHLLIMLWFJFE-UHFFFAOYSA-N methyl 2-[6-ethyl-7-[(3-fluorophenyl)methyl]-2-methylsulfanyl-5-oxamoylpyrrolo[2,3-d]pyrimidin-4-yl]oxyacetate Chemical compound CCC1=C(C(=O)C(N)=O)C2=C(OCC(=O)OC)N=C(SC)N=C2N1CC1=CC=CC(F)=C1 QJXHLLIMLWFJFE-UHFFFAOYSA-N 0.000 description 1
- RRKYFHSYPHNTJP-UHFFFAOYSA-N methyl 2-[6-ethyl-7-[(3-fluorophenyl)methyl]-5-oxamoylpyrrolo[2,3-d]pyrimidin-4-yl]oxyacetate Chemical compound CCC1=C(C(=O)C(N)=O)C2=C(OCC(=O)OC)N=CN=C2N1CC1=CC=CC(F)=C1 RRKYFHSYPHNTJP-UHFFFAOYSA-N 0.000 description 1
- GACWKGUHYXUDJG-UHFFFAOYSA-N methyl 2-[7-[(3-chlorophenyl)methyl]-6-ethyl-2-methylsulfanyl-5-oxamoylpyrrolo[2,3-d]pyrimidin-4-yl]oxyacetate Chemical compound CCC1=C(C(=O)C(N)=O)C2=C(OCC(=O)OC)N=C(SC)N=C2N1CC1=CC=CC(Cl)=C1 GACWKGUHYXUDJG-UHFFFAOYSA-N 0.000 description 1
- MVWAFQKBFWWTGK-UHFFFAOYSA-N methyl 2-[7-[(3-chlorophenyl)methyl]-6-ethyl-5-oxamoylpyrrolo[2,3-d]pyrimidin-4-yl]oxyacetate Chemical compound CCC1=C(C(=O)C(N)=O)C2=C(OCC(=O)OC)N=CN=C2N1CC1=CC=CC(Cl)=C1 MVWAFQKBFWWTGK-UHFFFAOYSA-N 0.000 description 1
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 description 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 125000004001 thioalkyl group Chemical group 0.000 description 1
- 125000004055 thiomethyl group Chemical group [H]SC([H])([H])* 0.000 description 1
- 125000005425 toluyl group Chemical group 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- 125000002256 xylenyl group Chemical group C1(C(C=CC=C1)C)(C)* 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US9124898P | 1998-06-30 | 1998-06-30 | |
| US60/091,248 | 1998-06-30 | ||
| PCT/US1999/014213 WO2000000201A1 (en) | 1998-06-30 | 1999-06-23 | BICYCLIC sPLA2 INHIBITORS |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2002519325A JP2002519325A (ja) | 2002-07-02 |
| JP2002519325A5 true JP2002519325A5 (enExample) | 2006-07-20 |
Family
ID=22226793
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000556786A Withdrawn JP2002519325A (ja) | 1998-06-30 | 1999-06-23 | 二環性ｓＰＬＡ２インヒビター |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US6384041B1 (enExample) |
| EP (1) | EP1091738B1 (enExample) |
| JP (1) | JP2002519325A (enExample) |
| AT (1) | ATE347362T1 (enExample) |
| AU (1) | AU4710699A (enExample) |
| CA (1) | CA2335448A1 (enExample) |
| DE (1) | DE69934311D1 (enExample) |
| WO (1) | WO2000000201A1 (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002000621A1 (en) * | 2000-06-29 | 2002-01-03 | Shionogi & Co., Ltd. | Compounds exhibiting x-type spla2 inhibiting effect |
| WO2002012249A2 (en) * | 2000-08-04 | 2002-02-14 | Eli Lilly And Company | Substituted pyrrole compounds and their use as spla2 inhibitors |
| US6730694B1 (en) | 2001-07-20 | 2004-05-04 | Eli Lilly And Company | sPLA2 inhibitors |
| GB0121033D0 (en) * | 2001-08-30 | 2001-10-24 | Novartis Ag | Organic compounds |
| AUPS282602A0 (en) | 2002-06-07 | 2002-06-27 | Garvan Institute Of Medical Research | Method of inhibiting cell proliferation |
| AR043692A1 (es) * | 2003-02-06 | 2005-08-10 | Novartis Ag | 2-cianopirrolopirimidinas y sus usos farmaceuticos |
| US20050124623A1 (en) | 2003-11-26 | 2005-06-09 | Bender John A. | Diazaindole-dicarbonyl-piperazinyl antiviral agents |
| US20060100432A1 (en) | 2004-11-09 | 2006-05-11 | Matiskella John D | Crystalline materials of 1-(4-benzoyl-piperazin-1-yl)-2-[4-methoxy-7-(3-methyl-[1,2,4]triazol-1-yl)-1H-pyrrolo[2,3-c]pyridin-3-yl]-ethane-1,2-dione |
| US7851476B2 (en) | 2005-12-14 | 2010-12-14 | Bristol-Myers Squibb Company | Crystalline forms of 1-benzoyl-4-[2-[4-methoxy-7-(3-methyl-1H-1,2,4-triazol-1-YL)-1-[(phosphonooxy)methyl]-1H-pyrrolo[2,3-C]pyridin-3-YL]-1,2-dioxoethyl]-piperazine |
| US7807671B2 (en) | 2006-04-25 | 2010-10-05 | Bristol-Myers Squibb Company | Diketo-piperazine and piperidine derivatives as antiviral agents |
| EP4008327A1 (en) | 2009-04-29 | 2022-06-08 | Amarin Pharmaceuticals Ireland Limited | Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same |
| WO2014033208A1 (en) | 2012-08-30 | 2014-03-06 | Qiagen Gmbh | A method for obtaining blood plasma from a whole blood sample |
| DE102012215957A1 (de) | 2012-09-10 | 2014-05-15 | Schaeffler Technologies Gmbh & Co. Kg | Resolverlager |
| DE102012023252B4 (de) | 2012-11-29 | 2016-11-10 | Selux Ag | Leuchte mit Elektroladestation für Elektrofahrzeuge |
| DE102013101611B3 (de) | 2013-02-19 | 2014-07-10 | HvS-Consulting AG | Verschlüsselungsverfahren für e-mails |
| DE102013022275A1 (de) | 2013-03-28 | 2014-10-02 | Elmos Semiconductor Ag | Straßenbeleuchtung |
| CN103204857A (zh) * | 2013-05-08 | 2013-07-17 | 兰州聚成生物科技有限公司 | 一种4-氯-2-(甲硫基)-7h-吡咯并[2,3-d]嘧啶的合成方法 |
| DE102013215468A1 (de) | 2013-08-06 | 2015-02-12 | Schaeffler Technologies Gmbh & Co. Kg | Tauchlageranordnung und Verfahren zur Abdichtung derselben |
| EP2902692B1 (de) | 2013-12-06 | 2017-10-25 | MAGNA STEYR Engineering AG & Co KG | Bauteil eines Tanksystems |
| US20170033433A1 (en) | 2014-04-14 | 2017-02-02 | Shanghai Amphenol Airwave Communication Electronics Co., Ltd. | Windshield Antenna |
| EP3396430B1 (en) | 2017-04-27 | 2023-08-16 | Euroimmun Medizinische Labordiagnostika AG | Optical scanning arrangement and method |
| WO2019050890A1 (en) * | 2017-09-05 | 2019-03-14 | President And Fellows Of Harvard College | METHODS AND COMPOSITIONS FOR THE TREATMENT OF TUBERCULOSIS |
| CN107915738B (zh) * | 2017-11-14 | 2019-07-26 | 海化生命(厦门)科技有限公司 | 用于合成巴瑞替尼的关键中间体2的制备方法 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3867386A (en) * | 1969-11-04 | 1975-02-18 | American Home Prod | 5-amino-2,6-substituted-7h-pyrrolo(2,3-d)pyrimidines and related compounds |
| US5916922A (en) * | 1996-12-03 | 1999-06-29 | Eli Lilly And Company | Phenyl glyoxamides as SPLA2 inhibitors |
-
1999
- 1999-06-23 EP EP99930602A patent/EP1091738B1/en not_active Expired - Lifetime
- 1999-06-23 DE DE69934311T patent/DE69934311D1/de not_active Expired - Lifetime
- 1999-06-23 JP JP2000556786A patent/JP2002519325A/ja not_active Withdrawn
- 1999-06-23 CA CA002335448A patent/CA2335448A1/en not_active Abandoned
- 1999-06-23 AU AU47106/99A patent/AU4710699A/en not_active Abandoned
- 1999-06-23 WO PCT/US1999/014213 patent/WO2000000201A1/en not_active Ceased
- 1999-06-23 AT AT99930602T patent/ATE347362T1/de not_active IP Right Cessation
- 1999-06-23 US US09/719,318 patent/US6384041B1/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2002519325A5 (enExample) | ||
| DK2614061T3 (en) | Quinoline and quinoxaline derivatives as kinase inhibitors | |
| CN104327084B (zh) | Bcr‑abl的小分子豆蔻酸酯抑制剂及其使用方法 | |
| IL256375A (en) | New histological histories, process for their preparation and pharmaceutical preparations containing them | |
| JP2005538992A (ja) | キナーゼ阻害剤 | |
| JP2007505933A5 (enExample) | ||
| KR102345381B1 (ko) | 키나제 억제제로서 유용한 카르바졸 카르복스아미드 화합물 | |
| US20110082147A1 (en) | Substituted imidazotriazines | |
| JP2009505988A5 (enExample) | ||
| JP2009523805A (ja) | ＴＮＦα、ＰＤＥ４及びＢ−ＲＡＦの阻害剤、それらの組成物及びそれらの使用法 | |
| RU2005117341A (ru) | Пиримидиновые соединения, обладающие антипролиферативной активностью (ii) | |
| JP2002541259A5 (enExample) | ||
| CN113754679B (zh) | 取代的嘧啶二酮类化合物及其用途 | |
| JP2016511240A (ja) | 置換二環式ジヒドロピリミジノン及び好中球エラスターゼ活性の阻害薬としてのそれらの使用 | |
| RU2403253C2 (ru) | Пуриновые производные для применения в качестве агонистов аденозинового рецептора а-2а | |
| US8993570B2 (en) | Substituted triazolo-pyridazine derivatives | |
| JP5980684B2 (ja) | ３−（インドリル）−または３−（アザインドリル）−４−アリールマレイミド化合物および腫瘍処置におけるそれらの使用 | |
| CA3187915A1 (en) | Atr inhibitors and uses thereof | |
| JP2002522385A5 (enExample) | ||
| JP2004501904A5 (enExample) | ||
| JP2006511498A5 (enExample) | ||
| TW200808317A (en) | Compounds for treating pulmonary hypertension | |
| RU2001128671A (ru) | Тиенопиримидиновые производные, их получение и применение | |
| CN105612150B (zh) | 磺酰吲哚衍生物和制备该磺酰吲哚衍生物的方法 | |
| US10357499B2 (en) | Substituted triazolobenzodiazepines |